The paper identifies DNA methylation changes during IDH-mutant glioma progression, links them to TET enzyme activity, and develops a methylation-based grading system that outperforms WHO grading.

Cell Reports Medicine · Mar 1, 2026Peer-reviewedCancer Biology

Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling

W. R. Vallentgoed, Youri Hoogstrate, Karin A. van Garderen, Levi van Hijfte, Erik van Dijk, Mathilde C.M. Kouwenhoven, Johanna M. Niers, Kaspar Draaisma, Ivonne Martin, Wendy W.J. de Leng, C. Mircea S. Tesileanu, Iris J. de Heer, Maud Diepeveen, Anna Lavrova, Paul P. Eijk, , Pim J. French

The paper analyzes multi-omics data from IDH-mutant astrocytomas to identify molecular markers of malignant progression linked to cell cycling and DNA methylation changes.

Nature Cancer · Aug 19, 2025Peer-reviewedCancer Biology

The epigenetic evolution of gliomas is determined by their IDH1 mutation status and treatment regimen

Tathiane Maistro Malta, Thaís S. Sabedot, Natalia S. Morosini, Indrani Datta, Luciano Garofano, Wies Vallentgoed, Frederick S. Varn, Kenneth Aldape, Fulvio D’Angelo, Spyridon Bakas, Jill S. Barnholtz‐Sloan, Hui Kong Gan, Mohammad Hasanain, Ann‐Christin Hau, Kevin C. Johnson, , Peter S. LaViolette

This study analyzes the epigenetic evolution of IDH1-mutant and IDH1-wildtype gliomas under treatment, showing IDHmut tumors undergo epigenomic changes resembling IDHwt tumors, with implications for treatment strategies.

Cancer Research · Dec 20, 2023Peer-reviewedGenomics